Get the Weekly Intelligence Brief — top committee picks every Sunday.
ERAS · NASDAQ · STOCK

Erasca, Inc.

Healthcare Updated August 11, 2026
$17.67
52W $1.33 – $24.28
62/100
$6.36B
-19.3
0.67
AI Committee Verdict
Buy
62/100
Conviction: Moderate · 60% agreement · 5 analysts
Moderate

Is ERAS Bullish or Bearish?

Bullish. Innellis AI committee rates Erasca, Inc. (ERAS) Buy with a composite score of 62/100 , based on 5 analysts with 60% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.42 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.58 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • ROE of only -77.0% -- cheap may mean cheap for a reason — Value
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 16.7% signals elevated volatility — Risk
  • No news coverage in the last 14 days -- limited independent confirmation either way — News
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
62/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 35%
of 192 Healthcare peers
Value Analyst neutral
52 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -77.0% -- cheap may mean cheap for a reason
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 16.7% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
60 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
48.1
Neutral
MACD Histogram
-0.204
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$8.71
Resistance
$24.28
Bollinger %B
0.35
Inside Bands
Price vs Moving Averages
EMA 9
$18.33 Below
EMA 21
$18.27 Below
EMA 50
$17.16 Above
EMA 200
$12.33 Above

Fundamental Analysis

Valuation
67
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio -19.3×
P/B Ratio 15.75×
PEG Ratio 0.17
Dividend Yield 0.00%
52W High $24.28
52W Low $1.33
Quality & Growth
ROE -3830.2%
ROA -3143.9%
Gross Margin 0.0%
Operating Margin 0.0%
Revenue Growth YoY
Debt / Equity 0.12
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -19.3 (inexpensive relative to a 15-40x range); Price-to-book of 15.8x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -38.3%; Return on assets of -31.4%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 8.29 (healthy short-term liquidity); Debt-to-equity of 0.12; Free cash flow per share is negative (-0.32); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ERAS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore ERAS Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime